Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

“Our software updates reflect the needs our customers communicate to us, and GastroPlus 9.9 is no exception,” said Neil Miller, Vice President of Simulation Sciences at Simulations Plus. “We ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

CEO Shawn M. O'Connor reported, "Third quarter revenue came in slightly above our preliminary range communicated in June. Final results showed revenue growth of 10% to $20.4 million, including a $2.4 ...

Image source: Getty Images. Simulations Plus reported a 6% revenue decline in the fourth quarter to $17.5 million, with sales sinking across software and services. That revenue was slightly ahead of ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their momentum that ...

Simulations Plus (NASDAQ:SLP) will release its quarterly earnings report on Monday, 2025-12-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Simulations Plus to ...

Webcast links will be available on the Investor Relations section of our website. For more information about the events or questions about registration, interested parties should reach out to their ...